Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Mobic, Vivlodex (lower-dose capsules), Anjeso (IV) (1)

Amphetamine (1) · Analgesic (2) · Opioid (2) · preferential COX-2)]] (1) · Prodrug (1) · Research material (1) · Stimulant (1) · [[:Category:Analgesics|Analgesic]] (1) · [[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID (1)

Monoamine releasing agent (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-00000019-QINU`"' Once-daily dosing is a clinical advantage over short-half-life NSAIDs'"`UNIQ--ref-0000001A-QINU`"'. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1)

None (2) · 7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (2) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tablets 7.5, 15 mg (Mobic); capsules 5, 10 mg (Vivlodex); oral suspension 7.5 mg/5 mL; injection 30 mg/mL (Anjeso) (1)

None (2) · 15 mg/day (oral); 30 mg IV once daily (Anjeso) (1) · 360 mg/day (1)

None (2) · intravenous (1) · Oral (1) · PO (only formulation marketed in the US). (1)

None (2) · 30–60 min (PO) (1) · Analgesic effect within hours; full anti-inflammatory effect over 1-2 weeks (1)

None (2) · 24 hours (once-daily dosing supported by long half-life) (1) · 4–6 hours (1)

None (2) · 15-20 hours'"`UNIQ--ref-00000020-QINU`"' (1) · 2.5–3 hours (1)

None (2) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~89% (oral)'"`UNIQ--ref-00000021-QINU`"' (1)

None (2) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000022-QINU`"' (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)